Other · developed by Nanobiotix
NBTXR3 is an agent injected into the prostate gland before intensity-modulated radiation therapy (IMRT), and it is studied in prostate cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02805894 | Phase 1/2 | Prostate Cancer | Terminated | NBTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Prostate Cancer
Updated Oct 25, 2026. Something wrong or missing? Report it on the NBTX page.
See NBTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NBTX catalysts and pipeline →